Trump’s executive order halts an effort to cap the copayment for generic medications at $2 for Medicare beneficiaries.

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.

Medicare announced plans to negotiate lower prices for 15 costly drugs, including Ozempic, Wegovy, and Trelegy Ellipta, starting in 2027. These medications, used for conditions like diabetes, weight loss, and asthma, accounted for $41 billion in Medicare spending last year. Novo Nordisk’s drugs alone cost $14.4 billion.

Medicare Payment Advisory Commission recommends tying physician payment update to care cost growth; AMA calls for Congress to act on analysis.

Under legislation passed in 2022 called the Inflation Reduction Act, Medicare was allowed for the first time to negotiate prices with drug companies on a limited number of medications.

Hospitals are also seeing higher uncompensated care as individuals lose Medicaid coverage or decide not to purchase health insurance. If there are changes to the health insurance exchanges, more people could end up uninsured. Hospitals across the country, and particularly safety-net hospitals, are preparing for the worst.

In 2025, more than 3 million seniors are going to save thousands of dollars because of a new spending limit on prescription drugs. It's unclear whether the Trump Administration will keep the law.

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

U.S. Senator Jacky Rosen announced that 15 additional medications have been selected for Medicare drug pricing negotiations, aiming to reduce costs for seniors

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.

Ozempic was one of the 15 drugs selected for the 2027 Medicare drug price negotiation program three days before President-elect Donald Trump takes office.